September 26, 2026 · 7 min read

Quitting Cigarettes Raised the Odds of Addiction Recovery by 30% — and Addiction Programs Still Treat Smoking as an Afterthought — Here’s What Every PMHNP Student Needs to Know

A single cigarette snapped in half on a slate windowsill beside a glass of water

He’s 90 days sober from alcohol. He shows you his chip. He’s going to meetings, his liver enzymes are coming down, and his wife is talking to him again. He’s also smoking a pack and a half a day, up from a pack when he was drinking.

You ask about the cigarettes. He laughs a little. “One thing at a time. My sponsor says don’t try to quit everything at once.”

Most of us would nod and move on. It sounds kind. It sounds realistic. It’s also the conventional wisdom that addiction treatment has leaned on for decades: cigarettes are the lesser evil, and pushing a patient to quit smoking in early recovery might knock loose the sobriety they’ve worked so hard for.

The evidence says that instinct is wrong. And if you’re going to be the prescriber in that room, you need to know why.

The study that tested the “one thing at a time” rule

In August 2025, JAMA Psychiatry published a study by Michael J. Parks and colleagues, including Wilson Compton, MD, deputy director of the National Institute on Drug Abuse (NIDA). The team used four waves of data, collected between 2013 and 2023, from the Population Assessment of Tobacco and Health (PATH) Study, a nationally representative cohort funded by the NIH and the FDA.

They followed 2,652 adults with a history of substance use disorder whose recovery status changed during the four years. “Recovery” meant past-year remission from SUD symptoms. The design is the clever part. Instead of comparing smokers to nonsmokers (two groups that differ in a hundred ways), the researchers compared each person to themselves: were they more likely to be in recovery during the years they had quit cigarettes than during the years they were still smoking?

They were. In the fully adjusted models, quitting smoking was tied to about a 30% greater likelihood of being in recovery from alcohol or other drugs. That held after accounting for changes in mental health and health care use. NIH’s announcement of the findings put one version of the estimate at 42% greater odds.

“We now have strong evidence from a national sample that quitting cigarette smoking predicts improved recovery from other substance use disorders,” NIDA director Nora Volkow, MD, said when the results were released. Compton added something every student should underline: smoking cessation “has not been seen as a high priority in drug addiction treatment programs.”

What Carlat says about the chicken-and-egg problem

Here’s the objection any good clinician raises right away. Maybe quitting smoking doesn’t help recovery. Maybe people who are already doing well just have the bandwidth to quit smoking too. That’s reverse causation, and it’s the first thing you should ask about any observational study.

Dr. Noah Capurso, editor-in-chief of The Carlat Addiction Treatment Report, walked through exactly this in the July/August/September 2026 issue, which was devoted to medical workers and addiction. The researchers checked whether quitting smoking in one year predicted recovery the following year. It did, and the effect was a little stronger, which points toward quitting smoking actually supporting sobriety rather than just tagging along with it.

Then the finding that should put the “don’t rock the boat” worry to rest: quitting smoking was not linked to worse mental health or clinical destabilization. If anything, mental health improved alongside recovery.

The Carlat Take was blunt. The study challenges the idea that smoking is a “lesser evil” in recovery, and if a patient with an SUD is ready to quit smoking, there’s no reason to delay.

The NIH was careful to note that more research is needed to prove cause and effect. That’s fair. But this isn’t the first time the data have pointed this way.

An empty circle of wooden chairs in a sunlit recovery center group room

This isn’t a new finding. It’s a finding we keep ignoring.

Back in 2004, Judith Prochaska, Kevin Delucchi, and Sharon Hall published a meta-analysis in the Journal of Consulting and Clinical Psychology covering 19 randomized trials of smoking cessation interventions for people in addiction treatment or recovery. The headline: offering smoking cessation during addiction treatment was associated with a 25% increased likelihood of long-term abstinence from alcohol and illicit drugs.

Twenty years later, the national PATH data point the same direction. That’s two very different kinds of evidence, randomized trials and a population cohort, landing in the same place.

And here’s the number that reframes the whole conversation. In a 1996 JAMA study, Richard Hurt and colleagues at Mayo Clinic followed people who had gone through inpatient addiction treatment in Olmsted County, Minnesota. Among those who died, about 51% of deaths were tobacco-related, compared with about 34% from alcohol-related causes.

Read that again. Your sober patient with the 90-day chip is more likely to die from the cigarettes than from the drinking. “One thing at a time” sounds gentle, but it means leaving the leading killer untreated.

Why PMHNP students should care about this right now

You’re going to see this patient constantly. Tobacco use is far more common in people with SUDs and serious mental illness than in the general population, and psychiatric and addiction settings are where many of those smokers will actually see a prescriber. Primary care might ask about smoking once a year. You might see that patient every month.

That makes you one of the best-positioned clinicians in the whole system to treat tobacco use disorder. The question is whether you’ll treat it like a real diagnosis or like background noise.

A few things to get straight now, before you’re in practice.

Tobacco use disorder is a DSM-5-TR substance use disorder

It uses the same 11-criterion framework as alcohol, cannabis, or opioid use disorder: loss of control, craving, failure to meet obligations, continued use despite problems, tolerance, withdrawal, and the rest. Severity follows the same cutoffs: 2 to 3 criteria is mild, 4 to 5 is moderate, 6 or more is severe. If your documentation lists “alcohol use disorder, severe, in early remission” and just “smoker” underneath it, you’re treating one addiction as a disease and the other as a habit.

Know nicotine withdrawal cold

DSM-5-TR tobacco withdrawal includes irritability or anger, anxiety, difficulty concentrating, increased appetite, restlessness, depressed mood, and insomnia. Symptoms usually peak in the first week and ease over two to four weeks. This matters for boards and for real life. A patient who quits smoking and suddenly looks anxious, irritable, and sleepless may be in withdrawal, not relapsing into a mood disorder. Don’t reach for a new psychiatric diagnosis before you’ve asked when they last smoked.

A hillside trail forking at a fence post, one path climbing toward a sunlit oak tree

The first-line medications

  • Varenicline: a partial agonist at the alpha-4 beta-2 nicotinic receptor. It blunts cravings and reduces the reward from a cigarette. The large EAGLES trial, published in The Lancet in 2016, included smokers with psychiatric disorders and did not find a significant increase in neuropsychiatric adverse events with varenicline or bupropion compared with placebo. The FDA removed the boxed warning later that year. If your preceptor still hesitates to use varenicline in psychiatric patients, that fear comes from data that were replaced a decade ago.
  • Bupropion SR: useful when depression and smoking travel together. Remember the seizure contraindications: seizure disorder, current or prior bulimia or anorexia nervosa, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptics. That last one matters a lot here. A patient in active alcohol withdrawal is not your bupropion candidate.
  • Combination nicotine replacement: a long-acting patch plus a short-acting form (gum, lozenge, inhaler, or nasal spray) works better than a single product. Many patients underdose NRT. Heavy smokers often need more than one patch strength or more frequent short-acting doses.

The interaction that will bite you

Tobacco smoke, not nicotine, induces CYP1A2 through the polycyclic aromatic hydrocarbons in the smoke. When a patient quits smoking, CYP1A2 activity drops and levels of drugs like clozapine and olanzapine can climb over the following days to weeks. Switching to a patch or gum won’t prevent that, because nicotine itself isn’t the inducer. When your patient quits, plan for dose adjustments and drug levels where relevant. You’ll see this on boards, and you’ll see it on the unit.

What to actually say to that patient

Go back to the man with the 90-day chip. You don’t have to lecture him. You don’t have to demand he quit today. But you also don’t have to agree that cigarettes are off-limits for another year.

Try something like: “I’m really glad you told me about the cigarettes. I want you to know something that surprised a lot of people in addiction medicine. A national study found that people who quit smoking during recovery were more likely to stay in recovery, not less. And quitting didn’t make their mental health worse. So if you’re ever curious about it, I’d be glad to help, and there are medications that make it a lot easier.”

That’s it. You’ve corrected a myth, respected his autonomy, and opened a door. That’s motivational interviewing in about thirty seconds. Ask again at the next visit. Readiness changes, and you want to be there when it does.

The bigger lesson for your career

This topic is a good reminder that some of the most confident “rules” in clinical practice were never built on strong evidence. “Don’t try to quit everything at once” came from good intentions and clinical folklore. When the data finally arrived, they pointed the other way.

Your job as a future PMHNP isn’t only to memorize what the field believes. It’s to keep asking, “What’s the evidence for that?” Sometimes the answer will confirm what your preceptor taught you. Sometimes, like here, it’ll give you a chance to do better for patients who’ve been told to wait.

Tobacco use disorder is treatable. It’s on your exam. And for many of your patients, it’s the addiction most likely to shorten their lives. Treat it like it matters, because it does.

Keep building your edge

Topics like this, where pharmacology, DSM-5-TR criteria, drug interactions, and real patient conversations all overlap, are exactly what shows up on the PMHNP boards. If you want practice questions, clear explanations, and a study plan that actually fits your life, head to PMHNPReview.org and start preparing with a resource built for students like you. You’ve got this, and we’ll help you get there.